Jackson Gibbs Jackson Gibbs
Adjunct Professor of Biochemistry and Molecular Medicine

Office Phone: 202-994-3539
Email: Email
Department: Biochemistry and Molecular Medicine

Education

  • Bachelor of Arts - Biological Sciences, Bucknell University, 1977
  • Ph.D. Pharmacology Degree, University of Virginia School of Medicine, 1982

Biography

GEORGE WASHINGTON UNIV. SCHOOL OF MEDICINE AND HEATH SCIENCES
Adjunct Professor, Dept. of Biochemistry and Molecular Medicine                      2015 - Present
 
Synergy Partners R&D Solutions
Network Partner/Consultant to the Bio-Pharmaceutical Industry                2014-Present                                                     
Driving drug discovery and development by synergistic collaboration.  Engage with academic collaborators.  Direct drug discovery via CRO’s.
 
JBG Pharma Consulting
Independent Pharmaceuticals Professional                                                                      2012-Present
Specializing in Oncology and Pharmacology R&D ("Drug Hunting") including:
General pharmacology
Scientific evaluations
Licensing evaluations/Due Diligence
Preclinical drug development
Translational Science
Project and Portfolio management (Tactical and Strategic)
Alliance management
Academic/Industry relations
Clients: Biotech Companies, Academic Institutions, Nonprofit Organizations (Foundations), Venture Capital and Law Firms
 
ASTRAZENECA PHARMACEUTICALS, Waltham, MA                                                              2006- 2012

Director, Licensing and Scientific Affairs, Cancer Research

Developing and implementing external scientific strategy, Licensing prioritization and evaluations, Leading/Managing external Alliances, Portfolio management
 
UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE
Adjunct Professor of Pharmacology                                                                                             2004 – 2007
Adjunct Associate Professor of Pharmacology                                                                           1992 – 2003
 
 
MERCK RESEARCH LABORATORIES, West Point, PA & Boston, MA                                      1982 – 2005
Senior Director, Cancer Research                                                                                                    1995-2005
Director, Cancer Research                                                                                                                 1993-1995
Associate Director, Cancer Research                                                                                               1990-1993
Research Fellow                                                                                                                                  1988-1990
Senior Research Biochemist                                                                                                              1985-1988
Postdoctoral Scientist                                                                                                                         1982-1985
Basic cancer research, Cancer drug discovery - 3 programs went into clinical trials (was co-Chair of Project Development team for one program), Licensing evaluations, External scientific liaison
 
EDUCATION
 
B.A., Biology/Chemistry, BUCKNELL UNIVERSITY, 1977
Ph.D., Pharmacology (1982), UNIVERSITY OF VIRGINIA, 1981
       Advisor: Gary Brooker (cAMP)
Biochemistry, GEORGETOWN UNIVERSITY, 1982
 
PROFESSIONAL DEVELOPMENT
 
Postdoctoral Fellowship, Merck Research Laboratories,
       Advisor: Edward Scolnick (ras)

PUBLICATIONS

Dr. Gibbs is co-inventor on five U.S. issued patents and an author of 128 research articles, book chapters, and review articles.  Some of the invited review articles (published in Cell and Science) focused on the interface between basic research and drug discovery in oncology.  Selected publications:
  1. Gibbs, J.B., Sigal, I.S., Poe, M. and Scolnick, E.M. (1984).  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.  Proc. Natl. Acad. Sci. USA 81:5704-5708. 
  2. Temeles, G.L., Gibbs, J.B., D’Alonzo, J.S., Sigal, I.S. and Scolnick, E.M. (1985).  Yeast and mammalian ras proteins have conserved biochemical properties.  Nature 313:700-703.
  3. Gibbs, J.B., Sigal, I.S. and Scolnick, E.M. (1985).  Biochemical properties of normal and oncogenic ras p21.  Trends Biochem. Sci. 10:350-353.
  4. Gibbs, J.B., Schaber, M.D., Allard, W.J., Sigal, I.S. and Scolnick, E.M., (1988).  Purification of ras GTPase activating protein from bovine brain.  Proc. Natl. Acad. Sci., USA, 85:5026-5030. 
  5. Sigal, I.S., Marshall, M.S., Schaber, M.D., Vogel, U.S., Scolnick, E.M. and Gibbs, J.B. (1988).  Structure/Function Studies of the ras Protein.  Cold Spring Harbor Symposium on Quantitative Biology, 53:863-869.
  6. Vogel, U.S., Dixon, R.A.F., Schaber, M.D., Diehl, R.E., Marshall, M.S., Scolnick, E.M., Sigal, I.S. and Gibbs, J.B. (1988).  Cloning of bovine GAP and its interaction with oncogenic ras p21.  Nature 335:90-93.
  7. Schaber, M.D., O’Hara, M.B., Garsky, V.M., Mosser, S.D., Bergstrom, J.D., Moores, S.L., Marshall, M.S., Friedman, P.A., Dixon, R.A.F. and Gibbs, J.B. (1990).  Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase.  J. Biol. Chem., 265:14701-14704.
  8. Gibbs, J.B., Marshall, M.S., Scolnick, E.M., Dixon, R.A.F. and Vogel, U.S. (1990).  Modulation of guanine nucleotides bound to Ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP).  J. Biol. Chem. 265:20437-20442.
  9. Gibbs, J.B. (1991).  Ras C-terminal processing enzymes - new drug targets?  Cell 65:1-4.
  10. Gibbs, J. B., Pompliano, D. L., Mosser, S. D., Rands, E., Lingham, R B., Singh, S. B., Scolnick, E. M., Kohl, N. E., and Oliff, A. (1993).  Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo.  J. Biol. Chem. 268:7617-7620.
  11. Omer, C.A., Kral, A.M., Diehl, R.E., Prendergast, G.C., Powers, S., Allen, C.M., Gibbs, J.B., and Kohl, N.E. (1993).  Characterization of recombinant human farnesyl-protein transferase: Cloning, expression, farnesyl diphosphate binding and functional homology with yeast prenyl-protein transferases.  Biochemistry 32:5167-5176.
  12. Kohl, N.E., Mosser, S.D., deSolms, S.J., Giuliani, E.A., Pompliano, D.L., Graham, S.L., Smith, R.L., Scolnick, E.M., Oliff, A., and Gibbs, J.B. (1993).  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.  Science 260:1934-1937.
  13. Gibbs, J.B., Oliff, A., and Kohl, N.E. (1994). Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.  Cell 77: 175-178.
  14. Gibbs, J.B. and Oliff, A. (1994). Pharmaceutical research in molecular oncology.  Cell 79: 193-198.
  15. Tang, Y., Chen, Z., Ambrose, D., Liu, J., Gibbs, J. B., Chernoff, J., and Field, J. (1997). Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.  Molec. Cell. Biol. 17: 4454-4464.
  16. Gibbs, J. B. (2000) Mechanism-based target identification and drug discovery in cancer research.  Science 287: 1969-1973.
  17. Sepp-Lorenzino, L., Rands, E., Mao, M. , Connolly, B., Shipman, J., Antanavage, J., Hill, S., Davis, L., Beck, S., Rickert, K. , Coll, K., Ciecko, P., Fraley, M., Hoffman, W., Hartman, G., Heimbrook, D., Gibbs, J., Kohl, N., and Thomas, K. (2004) A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo. Cancer Res. 64: 751-756
  18. Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, J. B., Pan, B.-S. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.  Cancer Res. 67: 2081-2088
  19.  Pan, B-S., Chan, G., Chenard, M., Davis, L.J., Deshmukh, S., Gibbs, J.B., Gil, S., Hang, G., Hatch, H., Jewel, J., Kariv, I., Katz, J., Kunii, K., Lu, W., Lutterbach, B., Paweletz, C., Qu, X., Reilly, J.F., Szewczak, A., Zeng, Q., Kohl, N.E., Dinsmore, C. J. (2010) MK-2461, a novel multi-targeted kinase inhibitor which preferentially inhibits the activated c-Met.  Cancer Res., 70: 1524-1533

Dr. Gibbs also has been actively involved with the external scientific community.  He has made over 100 presentations at universities and meetings. He has been asked to Chair or be a Keynote speaker at several such events, including serving as the foreign organizer and Keynote speaker of the 2004 Princess Takamatsu Cancer Fund Symposium.


PROFESSIONAL HONORS/ADVISORY BOARDS
 
Research Advisory Board, Children’s Tumor Foundation (formerly the National Neurofibromatosis Foundation), 1993-2015
Scientific Review Panel, New Jersey Commission on Cancer Research, 1995-2001
NCI Working Group - Preclinical models of cancer, 1996
U.S. Army Grant Review Panel, Neurofibromatosis, 1997
Corporate Relations Committee, Cancer Institute of New Jersey, 1998-2003
Scientific organizing committee and Chair of Opening session, 2003 AACR-NCI-EORTC international conference, Boston
Scientific organizing committee and Keynote Speaker, 2004 Princess Takamatsu Cancer Fund Symposium
Integration Panel, U.S. Army Medical Research Programs (Neurofibromatosis and Tuberous Sclerosis), 2001-2006
Chair-Elect/Chair/Chair Emeritus, Integration Panel, U.S. Army Medical Research Programs (Neurofibromatosis), 2003-2006
Advisor to the Drug Discovery Initiative, Children’s Tumor Foundation, 2006-present
External Advisory Board of the NF Consortium, Chair of the Preclinical group, 2007-2013
AACR Princess Takamatsu Memorial Lectureship Committee, 2008
Medical Affairs Committee reporting to the Board of Directors, Children’s Tumor Foundation, 2009-2012
AACR standing committee: Science Policy and Legislative Affairs, 2009-2012
Scientific organizing committee, AACR-NCI-EORTC meeting, Berlin, 2010
AACR Task Force on Regulatory Science and Policy, 2011-2012
Strategic Vision setting committees for the Children’s Tumor Foundation (2006, 2011), Lustgarten Foundation (Banbury Conference, 2008), and the Multiple Myeloma Research Foundation (2011, 2012)
External Advisory Board, Fox Chase Cancer Center, 2012-2014
Member, Scientific Review Committee of American MedChem, 2012-present
 
Editorial Boards
Exp. Opin. Invest. Drugs, 1994-2001
Exp. Rev. Anticancer Therapy, 2001-2005
IDrugs, 1998-2010
Int. J. Oncology, 1995-2002
J. Biol. Chem., 1995-2000
Molec. Cell. Biol., 1995-2000

 

Research

AREAS OF IINTEREST AND EXPERTISE
 
General
 

  • Biochemistry and Pharmacology, Pharmaceutical R&D, Extensive experience in evaluating/planning/managing research and drug discovery efforts
  • Portfolio management
  • Evaluation of licensing opportunities
  • External project liaison/consult; Served/Chaired on scientific advisory committees (academic, government, and nonprofit organizations)
  • Extensive journal editorial experience
 
Basic
 
  • Cancer biology and genetics, Neurofibromatosis (NF1 and NF2), Immuno-oncology, Inflammatory diseases, Fibrosis, Signal transduction, Epigenetics, Cell cycle regulation, Angiogenesis, G-proteins, Protein kinases
 
Applied
 
  • Target identification and validation
  • Assay development
  • Small molecule drug discovery (5 med-chem. supported projects; invited review articles on this topic in for example Ann. Rev. Pharm., Cell, J. Clin. Invest.,  Science)
  • Preclinical/Clinical development issues (co-Chaired a Product Development Team through phase I), prepare IND filings (FTI and VEGFRi); JRC for the AZD6244 + MK-2206 phase I
  • Plan and implement external scientific strategy (Alliances and Licensing) to fit global portfolio needs
  • Manage/guide Alliances and evaluate/advise in Due Diligence Teams for licensing opportunities

Teaching

Short lecture series within a course:
Nursing Pharmacology - Univeristy of Virginia
Undergraduate Biochemistry - Georgetown University
Graduate Pharmacology - University of Pennsylvania
Special lectures - Harvard Medical School
 

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None